Olema Pharmaceuticals (OLMA) Change in Account Payables (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Change in Account Payables of -$5.7 million for Q1 2026, down 31.84% year-over-year from -$8.3 million in Q1 2025, and down 198.41% quarter-over-quarter from $5.8 million in Q4 2025.
Powered by 
Analysis
Olema Pharmaceuticals (OLMA) Change in Account Payables (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Change in Account Payables for 7 consecutive years, with -$5.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 31.84% year-over-year to -$5.7 million; the TTM figure through Mar 2026 stood at $3.2 million (up 147.74% YoY), while the FY2025 annual figure was $4.6 million, up 83.19% from the prior year.
- Change in Account Payables declined to -$5.7 million in Q1 2026 per OLMA's latest filing, from $5.8 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $5.8 million in Q4 2025 and bottomed at -$5.7 million in Q1 2026.
- Historically, Change in Account Payables has averaged $241294.1 across 5 years, with a median of $360000.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Account Payables slumped 3060.0% — and 2024, when it soared 1514.98%.
- Olema Pharmaceuticals' Change in Account Payables stood at $360000.0 in 2022, then surged by 36.39% to $491000.0 in 2023, then jumped by 413.85% to $2.5 million in 2024, then soared by 128.81% to $5.8 million in 2025, then tumbled by 198.41% to -$5.7 million in 2026.
- Business Quant data shows OLMA's Change in Account Payables at -$5.7 million in Q1 2026, $5.8 million in Q4 2025, and $2.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Olema Pharmaceuticals | 1.13 Bn | 1.13 Bn | - | -1.91 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.91 Mn |
| Mar 31, 2026 | -5.68 Mn |
| Dec 31, 2025 | 5.77 Mn |
| Sep 30, 2025 | 2.39 Mn |
| Jun 30, 2025 | 743,000.00 |
| Mar 31, 2025 | -4.31 Mn |
| Dec 31, 2024 | 2.52 Mn |
| Sep 30, 2024 | -1.67 Mn |
| Jun 30, 2024 | -3.30 Mn |
| Mar 31, 2024 | 4.96 Mn |
| Dec 31, 2023 | 491,000.00 |
| Sep 30, 2023 | 582,000.00 |
| Jun 30, 2023 | 944,000.00 |
| Mar 31, 2023 | 307,000.00 |
| Dec 31, 2022 | 360,000.00 |
| Sep 30, 2022 | -106,000.00 |
| Jun 30, 2022 | -148,000.00 |
| Mar 31, 2022 | 245,000.00 |
| Dec 31, 2021 | -156,000.00 |
| Sep 30, 2021 | -205,000.00 |